10x Genomics, Inc.
Foreign stocks · NASDAQ · Healthcare · Genomic analysis tools
Makes instruments and reagent kits for single-cell gene analysis and tissue imaging, used by biology and medical researchers in the lab
Investors in Thailand can buy TXG through 14 mutual funds open to retail investors. Most of them (14 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds TXG.
| Fund | TXG weight | How it invests | 1-year return |
|---|---|---|---|
 ES-GENOMEEastspring Genomic Revolution Fund | 10.50% | Via several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +56.72% |
 |
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
| Master fund | Thai funds using this route | Master fund's TXG weight |
|---|---|---|
| Amova ARK Disruptive Innovation Fund | 4 | 3.77% |
| several master funds | 2 | 3.90% |
| iShares Russell 2000 ETF | 2 | 0.36% |
| several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | 1 | 10.50% |
| 8.02% |
| Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) |
| +61.33% |
 TGENOMETISCO Genomic Revolution Fund | 7.84% | Via several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | +54.22% |
 LHINNO-ALH INNOVATION FUND | 3.90% | Via several master funds | −12.68% |
| SCBINNO(A)SCB Innovation | 3.77% | Via Amova ARK Disruptive Innovation Fund | −9.90% |
 KFINNO-AKrungsri Disruptive Innovation Fund | 3.66% | Via Amova ARK Disruptive Innovation Fund | −12.64% |
| ES-GINNORMFEastspring Global Innovation RMF | 3.65% | Via Amova ARK Disruptive Innovation Fund | −12.39% |
| ES-GINNO-AEASTSPRING Global Innovation Fund | 3.63% | Via Amova ARK Disruptive Innovation Fund | −12.28% |
 ASP-IHEALTHAsset Plus Innovative Healthcare Fund | 2.62% | Via several master funds (JHHBIU2 LX, ARKG US) | +20.72% |
| ES-INTERNETEastspring Next Generation Internet Fund | 2.58% | Via several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | −14.52% |
Yearly average over the last 4 years · Latest annual sales 643.0M USD
For every 100 dollars of sales, about −7 dollars is left as net profit
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
Now 32.3% below its 1-year high
| Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | 490.0M USD | 516.0M USD | 619.0M USD | 611.0M USD | 643.0M USD |
| Gross profit | 416.0M USD | 396.0M USD | 409.0M USD | 414.0M USD | 444.0M USD |
| Operating profit |
| Period | SMA | EMA | Price vs line |
|---|---|---|---|
| 10 days | 72.06 | 70.67 | Below |
| 20 days | 72.89 | 72.93 | Below |
| 50 days | 74.16 | 70.93 | Below |
| 100 days | 60.17 | 61.57 | Above |
| 200 days |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 42.83 | Down |
| MACD(12,26) | −2.01 | Down |
| ADX(14) | 22.48 | Neutral |
| ATR(14) % of price | 5.84 | Neutral |
SCBAM3
BBLAM2TISCOASSET1LHFUND1KSAM1ASSETFUND1
DAOLINV1| Fund | TXG weight | Master fund | 1-year return | TER |
|---|---|---|---|---|
| ES-GENOME | 10.50% | several master funds (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +56.72% | 1.25% |
| SCBGENOME(A) | 8.02% | several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | +61.33% | 0.62% |
| TGENOME | 7.84% | several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | +54.22% | 1.28% |
| LHINNO-A | 3.90% | several master funds | −12.68% | 1.58% |
| SCBINNO(A) | 3.77% | Amova ARK Disruptive Innovation Fund | −9.90% | 0.61% |
| KFINNO-A | 3.66% | Amova ARK Disruptive Innovation Fund | −12.64% | 1.54% |
| ES-GINNORMF | 3.65% | Amova ARK Disruptive Innovation Fund | −12.39% | 1.79% |
| ES-GINNO-A | 3.63% | Amova ARK Disruptive Innovation Fund | −12.28% | 1.77% |
| ASP-IHEALTH | 2.62% | several master funds (JHHBIU2 LX, ARKG US) | +20.72% | 2.83% |
| ES-INTERNET | 2.58% | several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | −14.52% | 1.25% |
| BCAP-XHEALTH | 1.87% | several master funds | +17.62% | 1.23% |
| DAOL-USSMALL | 1.30% | FYC | N/A | 1.96% |
| SCBRS2000(A) | 0.36% | IWM | +10.46% | 1.17% |
| B-US2000P | 0.35% | IWM | +18.60% | 0.89% |
| several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | 1 | 8.02% |
| several master funds (ARK Genomic Revolution, iShares Genomics Immunology and Healthcare, ISHARES BIOTECHNOLOGY) | 1 | 7.84% |
| several master funds (JHHBIU2 LX, ARKG US) | 1 | 2.62% |
| several master funds (ARK Innovation UCITS, ARK NEXT GENERATION INTERNET ETF, ALPS O'Shares Global Internet Giants) | 1 | 2.58% |
| First Trust Small Cap Growth AlphaDEX® Fund | 1 | 1.30% |
| −52.0M USD |
| −168.0M USD |
| −265.0M USD |
| −195.0M USD |
| −61.0M USD |
| Net profit | −58.0M USD | −166.0M USD | −255.0M USD | −183.0M USD | −44.0M USD |
| EPS (diluted) | −0.53 | −1.46 | −2.18 | −1.52 | −0.35 |
| Gross margin | 84.9% | 76.7% | 66.1% | 67.8% | 69.1% |
| Operating margin | −10.6% | −32.6% | −42.8% | −31.9% | −9.5% |
| Net margin | −11.8% | −32.2% | −41.2% | −30.0% | −6.8% |
| Operating cash flow | −21.0M USD | −34.0M USD | −15.0M USD | 7.0M USD | 136.0M USD |
| Free cash flow | −123.0M USD | −165.0M USD | −64.0M USD | −6.0M USD | 130.0M USD |
| Total assets | 1.0B USD | 1.0B USD | 965.0M USD | 919.0M USD | 1.0B USD |
| Total liabilities | 201.0M USD | 223.0M USD | 224.0M USD | 209.0M USD | 245.0M USD |
| Shareholders' equity | 818.0M USD | 806.0M USD | 741.0M USD | 710.0M USD | 796.0M USD |
| 41.22 |
| 48.01 |
| Above |
